Olopatadine hydrochloride

DRUG3 trials

Sponsors

Allergy Therapeutics (UK) Limited, Laboratoires Thea, Laboratorios Sophia S.A de C.V.

Conditions

Allergic ConjunctivitisSeasonal Allergic ConjunctivitisSeasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen exposure

Phase 2

Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis

CompletedNCT01344083

Laboratoires TheaSeasonal Allergic Conjunctivitis

Start: 2011-04-30End: 2012-02-29Target: 60Updated: 2012-04-12

Phase 3

Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis

WithdrawnNCT01657240

Laboratorios Sophia S.A de C.V.Allergic Conjunctivitis

Start: 2014-11-30End: 2015-05-31Updated: 2018-10-02

A long-term, double-blind, randomised, placebo-controlled clinical trial to investigate the efficacy and safety of PQ Grass 27600 SU in children and adolescents with seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen exposure

RecruitingCTIS2023-508520-36-00

Allergy Therapeutics (UK) LimitedSeasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen exposure

Start: 2024-09-06Target: 358Updated: 2025-12-09